| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID4038: Therapeutics for people with COVID-19 |
|
Medicine details |
|
| Medicine name | sotrovimab (Xevudy®) |
| Formulation | 200 mg hard capsule |
| Reference number | 4793 |
| Indication | Treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40 kg) with acute covid-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe covid infection |
| Company | GlaxoSmithKline UK |
| BNF chapter | Infections |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 11/01/2022 |
| NICE guidance | |